Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis

Figure 1 Record selection process.

Figure 2 Risk of bias graph and summary.

Figure 3 Pooled analysis of objective response rate.

Figure 4 Pooled analysis of disease control rate.

Figure 5 Overall survival and progression-free survival. A: 6-mo overall survival (OS); B: 6-mo progression-free survival (PFS); C: 12-mo OS; D: 12-mo PFS.

Figure 6 Objective response rate of PD-L1 positive (A) and negative patients (B).

Figure 7 Comparison of objective response rate between PD-L1 positive and negative patients.

Figure 8 Pooled rate of any grade adverse events.

Figure 9 Pooled rate of grade ≥ 3 adverse events.